Clinical investigations begin long before the first patient
A successful clinical investigation rarely begins when the first participant signs an informed consent form. In reality, its success is often determined months earlier through planning, documentation, risk management and effective coordination. Yet these early activities are frequently underestimated, particularly by organisations preparing their first medical device clinical investigation.
“We have an innovative medical device. Now we’re ready for our clinical investigation.”
For many medical device manufacturers, particularly start-ups and small companies, this feels like the natural next milestone. But in reality, the success of a clinical investigation is often determined long before the first participant is enrolled.
Imagine a young MedTech company preparing for its first clinical investigation. The device performs as intended, funding has been secured and study sites are interested in participating. Everything appears to be in place — until the first challenges emerge. Responsibilities are still evolving, essential documentation is incomplete, external vendors have not yet been selected and assessed and project timelines suddenly become unrealistic.
None of these issues relate to the device itself. Yet each has the potential to delay study initiation.
This often-overlooked preparation phase is where successful clinical investigations truly begin. A structured Quality Management System (QMS), built on the principles of EN ISO 13485, provides the organisational framework needed to coordinate activities for clinical investigations regarding medical devices efficiently and consistently.
Why quality management matters before study start-up
When people think about quality management, they often associate it with regulatory compliance or certification. In practice, however, its value is much broader.
A well-established QMS helps organisations create clear responsibilities, maintain controlled documentation, manage changes, qualify suppliers and identify project risks before they become operational problems. Instead of reacting to unexpected issues during the study, teams can prepare for them in advance. This becomes particularly important during the study start-up phase, when numerous activities take place simultaneously. Clinical documentation must be finalised, vendors selected, study sites prepared and communication channels established. Without structured processes, even small uncertainties can quickly develop into significant delays.
Rather than adding bureaucracy, a QMS creates clarity. It enables everyone involved, from internal project teams to external partners, to work towards the same objective using consistent processes and clearly defined responsibilities.
How EN ISO 13485 supports clinical investigations
Although EN ISO 13485 does not describe how a clinical investigation should be conducted, many of its core principles directly support successful clinical study preparation.
Clear responsibilities ensure that project decisions are made efficiently and that communication remains transparent throughout the study. Effective document control guarantees that all stakeholders work with the latest approved document version, reducing the risk of inconsistencies across participating sites.
The standard also promotes risk-based thinking. While risk management is often associated with product development, it plays an equally important role during clinical investigations. Identifying recruitment challenges, operational risks or potential data quality issues early allows sponsors to implement mitigation measures before they affect study progress.
Another essential element is supplier management. Few manufacturers perform every clinical study activity internally. Monitoring, data management, laboratory analyses and biostatistics are frequently outsourced to specialised partners. A structured QMS helps organisations select qualified vendors, define responsibilities and maintain effective oversight throughout the project.
“Good clinical investigations don’t happen by chance, they result from structured planning, clear responsibilities and effective quality management.”
Taken together, these principles do not simply support regulatory compliance, they create the conditions for a well-organised clinical investigation.
Common challenges for first-time sponsors and manufacturers
Many start-ups are built around excellent ideas and highly innovative technologies. Clinical development, however, introduces challenges that extend far beyond product innovation.
One of the most common misconceptions is that clinical planning begins once the device is technically ready. In reality, many of the most important decisions are made much earlier.
Typical challenges include:
- involving clinical expertise too late in the development process
- underestimating the amount of study documentation required
- delaying vendor selection until shortly before study start
- unclear internal responsibilities as organisations continue to grow
- overly optimistic project timelines that fail to account for study preparation activities
None of these challenges are unusual. However, recognising them early allows to establish realistic plans, allocate resources more effectively and reduce the likelihood of costly delays.
Why early clinical project management matters
Clinical project management is often associated with coordinating activities after a study has already begun. In reality, much of its value is created during the preparation phase. Before the first participant can be enrolled, multiple workstreams need to progress in parallel. Documentation must be completed, timelines coordinated, vendors selected, risks assessed and communication established between all stakeholders. Without central coordination, these activities can quickly become fragmented, particularly in smaller organisations where individuals often perform multiple roles.
Early clinical project management brings these workstreams together into one coordinated project. It provides a structured approach to planning, aligns internal and external stakeholders and supports informed decision-making throughout study start-up. Seeking external clinical consulting at this stage can provide additional value. An experienced, independent perspective helps identify potential gaps, challenge assumptions and ensure that strategic decisions are made before they become costly changes later in the project.
For first-time sponsors and manufacturers, this proactive approach often translates into greater efficiency, fewer delays and a more predictable pathway towards generating high-quality clinical evidence.
Quality as the Foundation of Clinical Success
Clinical investigations are rarely defined by a single protocol or a single milestone. More often, they reflect the quality of the preparation that took place months before the first participant entered the study.
A robust QMS provides the structure. Early clinical project management transforms the structure into coordinated action.
Together, they enable sponsors, manufacturers or other stakeholders to navigate the complex preparation phase with greater confidence, reduce avoidable risks and establish the conditions for generating reliable clinical evidence.
Ultimately, the first patient may mark the visible beginning of a clinical investigation—but its success is often determined months earlier through careful planning, quality management and effective project coordination.
References
- International Organization for Standardization (ISO). EN ISO 13485:2016 – Medical devices – Quality management systems – Requirements for regulatory purposes. Geneva, Switzerland: ISO; 2016. Available at: https://www.iso.org/standard/59752.html (Accessed: June 2026).
- European Commission. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices (MDR). Available at: https://eur-lex.europa.eu/eli/reg/2017/745/oj (Accessed: June 2026).
- Medical Device Coordination Group (MDCG). MDCG 2024-3: Guidance on the content of the Clinical Investigation Plan for clinical investigations of medical devices. European Commission; 2024. Available at: https://health.ec.europa.eu/document/download/690de85a-ac17-45ea-bb32-7839540c25c4_en (Accessed: June 2026).
- European Commission. Guidance – MDCG endorsed documents and other guidance. Available at: https://health.ec.europa.eu/medical-devices-sector/new-regulations/guidance-mdcg-endorsed-documents-and-other-guidance_en (Accessed:June 2026).
Need assistance with planning and executing your clinical study or investigation?
We are always interested in exchanging perspectives with innovators, sponsors, and clinical partners working at the intersection of technology and vascular health.
Our team guides you through all steps of your clinical study, from selecting the optimal study design to compliant implementation. This way, you can save time and costs without compromising on quality. Use clinical studies as a strategic tool to advance your product development effectively and establish a strong foundation for a successful market launch.
We are here to help and support you in developing an optimal clinical strategy for safe, effective, and market-ready products. Our expert team ensures smooth planning and execution of clinical studies that meet both, regulatory requirements and your project goals.
Explore our website to learn more about how we can support you as a medical device manufacturer. Feel free to contact us at studien@vascage.at.
